Last reviewed · How we verify
KCT-0809
KCT-0809 is a small molecule that targets the SGLT2 receptor.
KCT-0809 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.
At a glance
| Generic name | KCT-0809 |
|---|---|
| Sponsor | Kissei Pharmaceutical Co., Ltd. |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 2 |
Mechanism of action
By inhibiting SGLT2, KCT-0809 reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This mechanism is particularly beneficial for patients with type 2 diabetes.
Approved indications
- Type 2 diabetes
Common side effects
- Increased risk of diabetic ketoacidosis
Key clinical trials
- An Extension Study of KCT-0809 in Dry Eye Patients With Sjögren's Syndrome (PHASE3)
- A Long-term Study of KCT-0809 in Dry Eye Patients With Sjögren's Syndrome (PHASE3)
- A Phase III Study of KCT-0809 in Dry Eye Patients With Sjögren's Syndrome (PHASE3)
- A Late Phase II Study of KCT-0809 in Patients With Dry Eye Syndromes (PHASE2)
- A Parallel Group Phase II Study of KCT-0809 in Patients With Dry Eye Syndromes (PHASE2)
- A Phase II Study of KCT-0809 in Patients With Dry Eye Syndrome (PHASE2)
- A Study of KCT-0809 in Patients With Dry Eye Syndromes (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- KCT-0809 CI brief — competitive landscape report
- KCT-0809 updates RSS · CI watch RSS
- Kissei Pharmaceutical Co., Ltd. portfolio CI